2001
DOI: 10.1093/bja/87.5.755
|View full text |Cite
|
Sign up to set email alerts
|

Structure, conformation, and action of neuromuscular blocking drugs †

Abstract: The author, his institutions of af®liation, and his colleagues have ®nancial interest in a series of novel bistropinium neuromuscular blocking (NMB) agents. Their work on that series of compounds is being sponsored in part by Organon, Inc. and was previously supported in part by Burroughs-Wellcome, Inc.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1

Citation Types

0
30
0

Year Published

2006
2006
2020
2020

Publication Types

Select...
7
1
1

Relationship

0
9

Authors

Journals

citations
Cited by 53 publications
(30 citation statements)
references
References 74 publications
0
30
0
Order By: Relevance
“…2 The strategy of bivalent ligands has been successfully implemented for searching for acetylcholinesterase inhibitors. 8,9 Furthermore, many of them have been tested as antimalarial drugs. There are some examples in the literature of dimeric molecules acquiring properties that are completely different from those of the precursor molecules.…”
Section: Introductionmentioning
confidence: 99%
“…2 The strategy of bivalent ligands has been successfully implemented for searching for acetylcholinesterase inhibitors. 8,9 Furthermore, many of them have been tested as antimalarial drugs. There are some examples in the literature of dimeric molecules acquiring properties that are completely different from those of the precursor molecules.…”
Section: Introductionmentioning
confidence: 99%
“…13 These data, however, may not be valid for vecuronium. Because the neuromuscular potency of vecuronium is six times greater than that of rocuronium (ED 95 = 0.05 and 0.30 mg/kg, respectively) 1 and their molecular weight is similar (637 and 610 Da, respectively, http://www.scbt.com/datasheet-205880.html; accessed December 15, 2015), fewer vecuronium than rocuronium molecules produce similar degrees of neuromuscular block. To encapsulate 1.0 mg vecuronium 3.4 mg of sugammadex is necessary, and to encapsulate the intubating dose (e.g., 7.0 mg), 2.4 mg sugammadex is sufficient.…”
mentioning
confidence: 99%
“…This type of anesthesia includes inhalational anesthesia [6] combined with intravenous administration of opioids [7], nondepolarizing M relaxation [8][9][10], and a continuous caudal epidural block [11].…”
Section: Discussionmentioning
confidence: 99%